Cargando…
Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer
PURPOSE: Tumor purity is defined as the proportion of cancer cells in the tumor tissue. The impact of tumor purity on colon cancer (CC) prognosis, genetic profile, and microenvironment has not been thoroughly accessed. MATERIALS AND METHODS: Clinical and transcriptomic data from three public dataset...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149864/ https://www.ncbi.nlm.nih.gov/pubmed/30271205 http://dx.doi.org/10.2147/CMAR.S171855 |
_version_ | 1783356885711192064 |
---|---|
author | Mao, Yihao Feng, Qingyang Zheng, Peng Yang, Liangliang Liu, Tianyu Xu, Yuqiu Zhu, Dexiang Chang, Wenju Ji, Meiling Ren, Li Wei, Ye He, Guodong Xu, Jianmin |
author_facet | Mao, Yihao Feng, Qingyang Zheng, Peng Yang, Liangliang Liu, Tianyu Xu, Yuqiu Zhu, Dexiang Chang, Wenju Ji, Meiling Ren, Li Wei, Ye He, Guodong Xu, Jianmin |
author_sort | Mao, Yihao |
collection | PubMed |
description | PURPOSE: Tumor purity is defined as the proportion of cancer cells in the tumor tissue. The impact of tumor purity on colon cancer (CC) prognosis, genetic profile, and microenvironment has not been thoroughly accessed. MATERIALS AND METHODS: Clinical and transcriptomic data from three public datasets, GSE17536/17537, GSE39582, and TCGA, were retrospectively collected (n=1,248). Tumor purity of each sample was inferred by a computational method based on transcriptomic data. Survival-related analyses were performed on microarray dataset containing GSE17536/17537 and GSE39582 (n=794), whereas TCGA dataset was utilized for subsequent genomic analysis (n=454). RESULTS: Right-sided CC patients showed a significantly lower tumor purity. Low purity CC conferred worse survival, and tumor purity was identified as an independent prognostic factor. Moreover, high tumor purity CC patients benefited more from adjuvant chemotherapy. Subsequent genomic analysis found that the mutation burden was negatively associated with tumor purity, with only APC and KRAS significantly more mutated in high purity CC. However, no somatic copy number alteration event was correlated with tumor purity. Furthermore, immune-related pathways and immunotherapy-associated markers (programmed cell death protein 1 [PD-1], programmed death-ligand 1 [PD-L1], cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], Lymphocyte-activation gene 3 [LAG-3] and T-cell immunoglobulin and mucin-domain containing-3 [TIM-3]) were highly enriched in low purity samples. Notably, the relative proportion of M2 macrophages and neutrophils, which indicated worse survival in CC, was negatively associated with tumor purity. CONCLUSION: Tumor purity exhibited potential value for CC prognostic stratification as well as adjuvant chemotherapy benefit prediction. The relative worse survival in low purity CC may attribute to higher mutation frequency in key pathways and purity-related microenvironmental changing. |
format | Online Article Text |
id | pubmed-6149864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-61498642018-09-28 Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer Mao, Yihao Feng, Qingyang Zheng, Peng Yang, Liangliang Liu, Tianyu Xu, Yuqiu Zhu, Dexiang Chang, Wenju Ji, Meiling Ren, Li Wei, Ye He, Guodong Xu, Jianmin Cancer Manag Res Original Research PURPOSE: Tumor purity is defined as the proportion of cancer cells in the tumor tissue. The impact of tumor purity on colon cancer (CC) prognosis, genetic profile, and microenvironment has not been thoroughly accessed. MATERIALS AND METHODS: Clinical and transcriptomic data from three public datasets, GSE17536/17537, GSE39582, and TCGA, were retrospectively collected (n=1,248). Tumor purity of each sample was inferred by a computational method based on transcriptomic data. Survival-related analyses were performed on microarray dataset containing GSE17536/17537 and GSE39582 (n=794), whereas TCGA dataset was utilized for subsequent genomic analysis (n=454). RESULTS: Right-sided CC patients showed a significantly lower tumor purity. Low purity CC conferred worse survival, and tumor purity was identified as an independent prognostic factor. Moreover, high tumor purity CC patients benefited more from adjuvant chemotherapy. Subsequent genomic analysis found that the mutation burden was negatively associated with tumor purity, with only APC and KRAS significantly more mutated in high purity CC. However, no somatic copy number alteration event was correlated with tumor purity. Furthermore, immune-related pathways and immunotherapy-associated markers (programmed cell death protein 1 [PD-1], programmed death-ligand 1 [PD-L1], cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], Lymphocyte-activation gene 3 [LAG-3] and T-cell immunoglobulin and mucin-domain containing-3 [TIM-3]) were highly enriched in low purity samples. Notably, the relative proportion of M2 macrophages and neutrophils, which indicated worse survival in CC, was negatively associated with tumor purity. CONCLUSION: Tumor purity exhibited potential value for CC prognostic stratification as well as adjuvant chemotherapy benefit prediction. The relative worse survival in low purity CC may attribute to higher mutation frequency in key pathways and purity-related microenvironmental changing. Dove Medical Press 2018-09-17 /pmc/articles/PMC6149864/ /pubmed/30271205 http://dx.doi.org/10.2147/CMAR.S171855 Text en © 2018 Mao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Mao, Yihao Feng, Qingyang Zheng, Peng Yang, Liangliang Liu, Tianyu Xu, Yuqiu Zhu, Dexiang Chang, Wenju Ji, Meiling Ren, Li Wei, Ye He, Guodong Xu, Jianmin Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer |
title | Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer |
title_full | Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer |
title_fullStr | Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer |
title_full_unstemmed | Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer |
title_short | Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer |
title_sort | low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149864/ https://www.ncbi.nlm.nih.gov/pubmed/30271205 http://dx.doi.org/10.2147/CMAR.S171855 |
work_keys_str_mv | AT maoyihao lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer AT fengqingyang lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer AT zhengpeng lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer AT yangliangliang lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer AT liutianyu lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer AT xuyuqiu lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer AT zhudexiang lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer AT changwenju lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer AT jimeiling lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer AT renli lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer AT weiye lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer AT heguodong lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer AT xujianmin lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer |